Next Article in Journal
Selective CNS Targeting and Distribution with a Refined Region-Specific Intranasal Delivery Technique via the Olfactory Mucosa
Next Article in Special Issue
Manganese-Doped N-Hydroxyphthalimide-Derived Carbon Dots—Theranostics Applications in Experimental Breast Cancer Models
Previous Article in Journal
The Use of Menthol in Skin Wound Healing—Anti-Inflammatory Potential, Antioxidant Defense System Stimulation and Increased Epithelialization
Previous Article in Special Issue
Development of Dextran-Coated Magnetic Nanoparticles Loaded with Protocatechuic Acid for Vascular Inflammation Therapy
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pharmaceutics
Volume 13
Issue 11
10.3390/pharmaceutics13111903
pharmaceutics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Brachytherapy Approach Using 177Lu Conjugated Gold Nanostars and Evaluation of Biodistribution, Tumor Retention, Dosimetry and Therapeutic Efficacy in Head and Neck Tumor Model

by
Min-Ying Lin
1,†,
Hsin-Hua Hsieh
1,†,
Jyh-Cheng Chen
1,
Chuan-Lin Chen
1,
Nin-Chu Sheu
1,
Wen-Sheng Huang
2,
Shinn-Ying Ho
3,
Ting-Wen Chen
3,4,
Yi-Jang Lee
1,5,* and
Chun-Yi Wu
1,*
1
Department of Biomedical Imaging and Radiological Sciences, National Yang Ming Chiao Tung University, Taipei Branch, Taipei 112, Taiwan
2
Department of Nuclear Medicine, Taipei Medical University Hospital, Taipei 11031, Taiwan
3
Institute of Bioinformatics and Systems Biology, National Yang Ming Chiao Tung University, Hsinchu Branch, Hsinchu 30068, Taiwan
4
Department of Biological Science and Technology, National Yang Ming Chiao Tung University, Hsinchu Branch, Hsinchu 30068, Taiwan
5
Cancer Progression Research Center, National Yang Ming Chiao Tung University, Taipei Branch, Taipei 112, Taiwan
*
Authors to whom correspondence should be addressed.
†
These authors contributed equally.
Pharmaceutics 2021, 13(11), 1903; https://doi.org/10.3390/pharmaceutics13111903
Submission received: 8 October 2021 / Revised: 2 November 2021 / Accepted: 5 November 2021 / Published: 9 November 2021
(This article belongs to the Special Issue Design of Multifunctional Nanomaterials for Diagnostic and Therapy: The Transition Pathway from Conventional to Personalized Medicine)
Browse Figures
Review Reports Versions Notes

Abstract

:
Brachytherapy can provide sufficient doses to head and neck squamous cell carcinoma (HNSCC) with minimal damage to nearby normal tissues. In this study, the β−-emitter 177Lu was conjugated to DTPA-polyethylene glycol (PEG) decorated gold nanostars (177Lu-DTPA-pAuNS) used in surface-enhanced Raman scattering and photothermal therapy (PTT). The accumulation and therapeutic efficacy of 177Lu-DTPA-pAuNS were compared with those of 177Lu-DTPA on an orthotopic HNSCC tumor model. The SPECT/CT imaging and biodistribution studies showed that 177Lu-DTPA-pAuNS can be accumulated in the tumor up to 15 days, but 177Lu-DTPA could not be detected at 24 h after injection. The tumor viability and growth were suppressed by injected 177Lu-DTPA-pAuNS but not nonconjugated 177Lu-DTPA, as evaluated by bioluminescent imaging. The radiation-absorbed dose of the normal organ was the highest in the liver (0.33 mSv/MBq) estimated in a 73 kg adult, but that of tumorsphere (0.5 g) was 3.55 mGy/MBq, while intravenous injection of 177Lu-DTPA-pAuNS resulted in 1.97 mSv/MBq and 0.13 mGy/MBq for liver and tumorsphere, respectively. We also observed further enhancement of tumor-suppressive effects by a combination of 177Lu-DTPA-pAuNS and PTT compared to 177Lu-DTPA-pAuNS alone. In conclusion, 177Lu-DTPA-pAuNS may be considered as a potential radiopharmaceutical agent for HNSCC brachytherapy.

1. Introduction

Head and neck squamous cell carcinoma (HNSCC) ranks sixth in incidence around the world. The 5-year survival rate of HNSCC is around 65% and locoregional recurrence is believed to be a major limitation of various treatments, including surgical and nonsurgical strategies [1,2]. Unlike other cancers that occur in parenchymal organs, the dissemination of HNSCC is mainly caused by local invasion instead of distant metastasis [3]. Local invasion of HNSCC is also a risk factor of recurrence after therapy, and the mechanism of local invasion has been reported to be associated with epithelial-mesenchymal transition (EMT) of tumor cells [4,5]. A recent report demonstrated that EMT can be regarded as a prognostic factor for HNSCC patients who undergo chemoradiotherapy [6]. Rhenium-188 composed of radiopharmaceuticals with diagnostic and therapeutic capacity also exhibit significant effects on repressing EMT markers of orthotopic HNSCC tumor model [7]. Radiopharmaceuticals or radionuclides are considered as neoadjuvant high-dose-rate brachytherapy for breast cancer or cervical cancer [8,9]. For recurrent HNSCC, high-dose-rate brachytherapy has also been reported to improve overall survival without unacceptable acute toxicity [10,11]. Therefore, the development of specific radiopharmaceuticals is needed for local treatment of advanced HNSCC and to reduce potential side effects raised by radioactivity.
Certain radionuclides emit both moderate- or high-energy particles and low-energy γ-rays that can be used for in vivo diagnosis and therapy concomitantly, the so-called theranostics. Lutetium-177 (177Lu) is probably the most attractive theranostic radionuclide contemporarily as it shows therapeutic advantages in various fields of preclinical and clinical communities [12,13,14]. 177Lu exists in an oxidative state of +3 charge that allows it to be easily radiolabeled to a variety of molecular carriers, and this property is important for the design of targeted radionuclide therapy (TRT) [15]. 177Lu emitted 78% of 0.497 MeV β− particles (Eβ(max)) and 11% of 0.208 MeV γ-rays that can be used for theranostics and dosimetry [16]. The therapeutic efficacy of moderate-energy β− particles can be compensated by a relatively long half-life (6.65 days) and high activity of 177Lu during the preparation of radiopharmaceuticals and administration to patients. The mean emission range of β− particles delivered by 177Lu is 670 μm [15]. The diameter of one mammalian cell is around 100 μm, therefore, 177Lu is ideal for the treatment of local invaded tumor cells and surface tumors with low damage to nearby normal tissues. Therefore, the physical and chemical characteristics of 177Lu seem applicable for its administration in local advanced HNSCC. However, little is known if 177Lu formed radiopharmaceuticals can be used for local theranostics of HNSCC, at least in a preclinical model.
Gold nanostars (AuNS) belong to a specific shape of gold nanoparticles (GNP) that constitute a solid metal core decorated with multiple sharp branches [17]. AuNS have been used as a substrate for surface-enhanced Raman scattering (SERS), localized surface plasmon resonance (LSPR) sensing, and refractive index (RI) sensing [18,19,20]. Studies have also demonstrated that AuNS are biocompatible and their biomedical applications, including diagnosis, bioimaging, photothermal therapy, and target drug delivery are of interest [21,22,23,24]. For instance, AuNS can be used as photothermal agents for cancer treatment because of the high conversion efficiency raised by the near-infrared (NIR) laser [25,26]. A similar approach using NIR light irradiation can also stimulate the release of a chemotherapeutic agent coated on AuNS [27]. However, whether AuNS can be used as a nanocarrier for radionuclides and applied in tumor imaging and therapy remains to be addressed. 177Lu-labeled GNP is found to be highly effective for inhibiting the growth of breast cancer in tumor-bearing mice by intratumoral administration [28], the radiolabeling of AuNS is also speculated to be also applicable to theranostics in the HNSCC tumor model.
Based on the promising theranostic properties of 177Lu and the nature of the gold nanostars, we aim to develop PEGylated coated AuNS for conjugating 177Lu via a DTPA chelator and determine their biodistribution by using noninvasive imaging as well as the therapeutic efficacy. To the best of our knowledge, this is the first report proposing the preclinical application of 177Lu labeled AuNS in the human HNSCC tumor model.

2. Materials and Methods

2.1. Preparation and Characterization of 177Lu-Labeled pAuNS (177Lu-DTPA-pAuNS)

The manufacturing procedure of gold nanostars (AuNS) has been described previously [26]. Poly(ethylene glycol) methyl ether thiol (45 mg, SH-PEG6000-CH3, Sigma-Aldrich, St. Louis, MO, USA) and Thiol PEG amine (15 mg, SH-PEG2K-NH2, Sigma-Aldrich, St. Louis, MO, USA) were added to the AuNS solution. The mixture was kept at room temperature for 2 h with gentle shaking. After the reaction, the solution was centrifuged at 12,000× g for 15 min to remove unconjugated compounds in the supernatant. The pellet was resuspended in ddH2O. To this solution, the chelate, p-SCN-Bn-DTPA (0.5 mg, Macrocyclics, Plano, TX, USA) dissolved in 0.05 M of sodium bicarbonate buffer (pH = 9.2), was added and the mixture was reacted at 60 °C for 4 h. The unreacted chelate was removed by centrifugation (12,000× g, 15 min) to give DTPA-pAuNS as a pellet, which was washed with ddH2O twice for radiolabeling. 177Lu-LuCl3 (ITG Isotope Technologies Garching GmbH, Garching, Germany) and DTPA-pAuNS (177Lu-LuCl3/DTPA-pAuNS = 10 μCi/1 μg) were added to a vial containing HEPES buffer (0.1 M, pH = 4.5) and the mixture was allowed to react at 30 °C for 30 min. After the reaction, excess DTPA solution (10 mM) was loaded for a 30-min challenge. Finally, the mixture was centrifuged at 10,000× g for 10 min to obtain the product, 177Lu-DTPA-AuNS. The labeling efficiency and radiochemical purity were determined by radio-thin layer chromatography (radio TLC) using sodium citrate buffer (0.5 M, pH = 5.0) as mobile phase on an ITLC plate (ITLC-SG, Merck, Darmstadt, Germany).

2.2. Cell Lines

Human tongue squamous cell carcinoma SAS cells were obtained from Prof. Muh-Hwa Yang (National Yang Ming Chiao Tung University, Taipei, Taiwan) and SAS-3R cells (a stable cell line with multiple reporter genes, including green fluorescent protein gene, firefly luciferase gene and herpes simplex virus type 1-thymidine kinase gene) harboring a pLT-3R construct with multiple reporter genes were maintained as described in a previous report [29]. Cells were maintained in DMEM (Life Technologies Inc., Carlsbad, CA, USA). All cell lines were supplemented with 10% fetal bovine serum (Thermo Fisher Scientific Inc., Waltham, MA, USA), 2 mM L-glutamine, and 50 U/mL penicillin. Cells were incubated at 37 °C in a humidified incubator containing 5% CO2.

2.3. Human HNSCC Tumor-Bearing Animal Model

The SAS-3R cells were implanted on BALB/c nude mice with orthotopic injection. The SAS-3R cells were carefully cultured and resuspended in OPTI-MEM (Sigma-Aldrich, St. Louis, MO, USA) at a concentration of 106 cells/50 μL. The mice were anesthetized and placed supine. The mouth was opened and the 27G needle syringe (Terumo Co., Tokyo, Japan) was then inserted for 5 mm and injected through the outer muscle of the lower jaw on the right side of mice. All the experiment animals were approved by the Institutional Animal Care and Use Committee (IACUC No. 1081009).

2.4. Analysis of Biodistribution of 177Lu-DTPA and 177Lu-DTPA-pAuNS

The tumor-bearing mice were randomly assigned to two groups for intratumoral injection of 177Lu-DTPA and 177Lu-DTPA-pAuNS followed by biodistribution. Mice were sacrificed by CO2 asphyxiation to collect organs and tumors after 4, 24, and 72 h of injection. Collected organs were weighed and counted by the γ-scintillation counter (1470 WIZARD Gamma Counter, Wallac, Finland). The results are presented as the percentage injected dose per gram tissue (% ID/g).

2.5. MicroSPECT Imaging of 177Lu-DTPA-pAuNS in Tumor-Bearing Mice

When the SAS-3R tumor volume reached 100–150 mm3, the mice were randomly categorized into three groups, (a) receiving intravenous (400 μCi/100 μL), (b) intratumoral injection of 177Lu-DTPA-pAuNS and (c) intratumoral injection of 177Lu-DTPA (200 µCi/50 µL), respectively. After administration of 177Lu-DTPA or 177Lu-DTPA-pAuNS, we performed microSPECT/CT imaging to acquire signals using the small animal PET/SPECT/CT scanner (FLEX Triumph Regular FLEX X-OCT, SPECT CZT 3 Head System, Gamma Medica, Northridge, CA, USA). Each tumor-bearing mouse was laid in the prone position and anesthetized with 1–2% isoflurane (w/v) in 2 L oxygen. The images were reconstructed by using an ordered-subsets expectation-maximization (OSEM) algorithm. For imaging conditions, since the scanner has still not yet set the imaging protocol of 177Lu, the protocol of 111In with similar gamma-ray energy was used for imaging. Each mouse was first positioned by CT scan, then a SPECT scan was performed for 30 min, and the image was reconstructed using OSEM with 20 iterations. We then used Amide’s Medical Image Data Examiner (AMIDE 1.0.4) software to perform semi-automatic region of interest (ROI) drawing and semi-quantitative analysis of the tumor areas in the reconstructed images. After each ROI was circled by AMIDE software, we calculated the cylinder factor obtained from the reference source. The procedure included (a) determining the activity by measuring with a well-type ion chamber, (b) keeping it in a cylindrical container with a fixed volume (cc), (c) scanning the cylinder, reconstructing the image and encircling the ROI and (d) calculating the cylinder factor. The cylinder factor and the injection activity of each mouse were input into AMIDE. Accordingly, we could obtain semi-quantitative data in %ID/cc as the unit.

2.6. Evaluation of Therapeutic Efficacy of 177Lu-DTPA-pAuNS in Tumor-Bearing Mice

For evaluation of therapeutic efficacy, the tumor viability and growth rate were assessed using the luciferase-based reporter gene imaging (IVIS 50, Perkin Elmer Inc., Waltham, MA, USA) and caliper measurement, respectively. A caliper was used to measure tumor dimensions and its size (mm3) was calculated as 0.5 × width2 × length. For survival analysis, the endpoint of each datum was established since the first mice died from the treatment. The Kaplan-Meier plot was used for demonstration of survival.

2.7. Evaluation of Therapeutic Efficacy of pAuNS-Mediated Optothermal Therapy

The mice in the control and treated group received intratumoral injections of 177Lu-DTPA and 177Lu-DTPA-pAuNS (10 mg/kg), respectively. After injection, a 6-min laser (793 nm, 1 W/cm2) exposure was performed. The increase in temperature was monitored by a digital thermometer using a thermocouple. The treatment response was determined by measuring tumor burden and hematoxylin and eosin staining.

2.8. Dosimetric Evaluation of 177Lu-DTPA-pAuNS Absorbed Radiation Dose In Vivo

For estimating the radiation absorption dose of various tissues/organs in the human body, the mean absorbed dose in various tissues was calculated from the radionuclide concentration in tissues/organs, and the relative tissue/organ weight was calculated based on previous studies. Based on the results of the biodistribution study in mice, the calculated mean value of the percentage of injected activity per gram of tissue/organ (%IA/g) was extrapolated to present the uptake in organs of a 73 kg adult using the following formula.
[(%IA/gorgan)mice × (kgtotal body weight)mice] × (gorgan/(Kgtotal body weight)human) = (%IA/organ)human
The extrapolated values (%IA) in the human organs at 4, 24, 48 and 72 h were exponentially fitted and integrated to obtain the number of disintegrations in source organs. The value of each source organ was entered into the OLINDA/EXM 1.0 software for the dosimetry estimation. For tumor absorbed dose, the number of disintegrations was calculated and entered into the sphere modeling of OLINDA/EXM 1.0 software to estimate the absorbed dose of tumor in each spheroid mass.

2.9. Hematoxylin and Eosin (H&E) Staining

Tumor sections were prepared for formalin-fixed paraffin-embedded tissues and selected according to the morphology catalog of the diagnosis. The sections were dewaxed in an oven at 60 °C, and de-paraffinized by xylene, followed by rehydration in an alcohol solution. The tissue sections were stained with hematoxylin and eosin.

2.10. Statistical Analysis

The results obtained in this study were analyzed by Student’s t-test, and p < 0.05 was determined as a significant difference. All data were represented as mean ± standard deviation or mean ± standard error of the mean. The Kaplan-Meier method with the log-rank test was used to compare survival rates among different treatments.

3. Results

3.1. Design of 177Lu Conjugated pAuNS for the Treatment of HNSCC In Vivo

The theranostic radionuclide 177Lu was conjugated to the PEGylated AuNS (pAuNS). Figure 1 illustrates the preparation of 177Lu conjugated pAuNS via DTPA chelator, the evaluation of tumor accumulation, dosimetry, and therapeutic efficacy after intratumoral administration. The radio TLC analysis showed that the labeling efficiency of 177Lu-DTPA-pAuNS was around 87%, and the EDTA challenge with excess EDTA did not significantly affect the labeling efficiency (Figure 1B). After purification by centrifugation, the radiochemical purity (RCP) was 95 ± 3% (Figure 1C). In addition, the radiochemical yield was 50 ± 5%, determined by the radioactivity of the final product over that of initially added 177Lu. The TEM visualization demonstrated that the shape and the size of pAuNS were not significantly changed before and after conjugation of 177Lu (Figure 1D).

3.2. Analysis of 177Lu-DTPA-pAuNS Biodistribution in an Orthotopic HNSCC Tumor Model

The biodistribution of intratumorally injected 177Lu-DTPA-pAuNS and 177Lu-DTPA was quantitatively analyzed. The results showed that the level of 177Lu-DTPA-pAuNS was still high in tumor lesions up to 72 h, whereas a little radioactivity was detected in the liver (Figure 2). Free 177Lu-DTPA was only detected in tumor lesions for 24 h and also very little in different organs. The tumor-to-muscle (T/M) and tumor-to-blood ratios (T/B) of 177Lu-DTPA-pAuNS at different time points were also calculated (Table 1). For intravenous injection of 177Lu-DTPA-AuNS, most of the drug was accumulated in the liver and kidney rather than tumors (Table S1).

3.3. MicroSPECT/CT for Evaluation of Intratumoral Injection in HNSCC Tumor

We next compared the tumorous accumulation of 177Lu-DTPA and 177Lu-DTPA-pAuNS in the orthotopic tumor model. The photon signals of 177Lu-DTPA-pAuNS injected tumor were significantly higher than that of 177Lu-DTPA injected tumor detected by μSPECT/CT imaging (Figure 3A). No photon signals were detected in other organs of tumor-bearing mice. The imaging result was also semi-quantified by measuring the mean radioactivity in each ROI (Figure 3B). Positive correlations of SPECT imaging and biodistribution were also observed in the tumor uptakes of 177Lu-DTPA-pAuNS and 177Lu-DTPA (Figure 3C,D).

3.4. Evaluation of Therapeutic Efficacy of 177Lu-DTPA-pAuNS and 177Lu-DTPA in Tumor-Bearing Mice

To evaluate the therapeutic efficacy of 177Lu-DTPA-pAuNS in vivo, SAS cells harboring the luciferase reporter gene were used for the establishment of an orthotopic tumor model followed by bioluminescent imaging. The schedule for tumor implantation, drug injection, and in vivo imaging are illustrated in Figure 4A. 177Lu-DTPA-pAuNS and 177Lu-DTPA (7.4 MBq each) were separately injected into the tumor lesions of small animals. The bioluminescent imaging was acquired using the IVIS 50 system. The results showed that 177Lu-DTPA-pAuNS suppressed the luciferase activity, but 177Lu-DTPA did not (Figure 4B). The photon flux was quantified to draft the curves for comparison (Figure 4C). The tumor growth curves also demonstrated reduced rates of tumor growth in the 177Lu-DTPA-pAuNS treated group (Figure 4D).

3.5. Increase of Survival Rate of HNSCC Tumor-Bearing Mice by 177Lu-DTPA-pAuNS

The body weights of mice did not decrease more than 80% after treatment of 177Lu-DTPA-AuNS or 177Lu-DTPA up to 20 days (Figure 5A). Intratumoral injection of 177Lu-DTPA-pAuNS showed a higher survival rate in tumor-bearing mice than 177Lu-DTPA (Figure 5B). Therefore, 177Lu-DTPA-pAuNS has the potential of good therapeutic efficacy by long-term tumor retention and low toxicity using the brachytherapy approach.

3.6. Estimation of Dosimetry in Human Organs by the Treatment of 177Lu-DTPA-pAuNS

The OLINDA/EXM method was used to estimate the absorbed radiation dose in systemic organs and tumor lesion of a 73 kg adult according to the biodistribution data in HNSCC tumor-bearing mice with intratumoral injection of 177Lu-DTPA-pAuNS. The results showed the highest absorbed dose in the liver (0.329 mSv/MBq), kidney (0.135 mSv/MBq), and spleen (0.138 mSv/MBq) (Table 2). The sphere model was used to estimate the absorbed dose of the tumor at 0.5 g (3.55 mGy/MBq), and it is significantly higher than that absorbed by all organs. The ratios of absorbed doses for tumor-to-brain and tumor-to-thyroid were 1517.1 and 2909.8, respectively. The estimated absorbed radiation dose in tumor-bearing mice intravenously injected with 177Lu-DTPA-pAuNS (Table 3) was 1.97, 0.16 and 1.37 mSv/MBq, respectively, in the liver, kidney, and spleen. However, the absorbed dose of 0.5 g tumorsphere was only 0.038 mGy/MBq. The ratios of absorbed doses for tumor-to-brain and tumor-to-thyroid were 9.9 and 0.54, respectively. Therefore, the intratumoral injection of 177Lu-DTPA-pAuNS was found to be more efficient in the delivery of radiation dose to the tumor but led to less radiation damage to vital organs compared to that by intravenous injection of 177Lu-DTPA-pAuNS.

4. Discussion

In this study, we applied brachytherapy for the treatment of orthotopic HNSCC tumors using intratumoral injection of 177Lu-DTPA-pAuNS. This local chemoradiotherapy method can deliver a relatively precise quantity of high-dose-rate radiopharmaceutical to specific tumor positions so that the risk of side effects is minimized [30,31,32]. Brachytherapy has also been applied in different types of HNSCC, including nasopharyngeal cancer, and oral cancer [33,34]. Although most nanocarriers for in vivo drug delivery are injected through vessels, nanoparticles are notorious for long-term accumulation in the liver and spleen by the reticuloendothelial system [35]. Therefore, the safety of radionuclide-conjugated nanoparticles is inevitably questioned because of radiation-induced damage to vital organs. The brachytherapy approach using intratumoral injection is a highly recommended route to be considered for preclinical and clinical treatment of HNSCC in a tumor model. The biodistribution analysis data have shown only a little dissemination of 177Lu-DTPA-pAuNS to normal organs away from the orthotopic tumor by intratumoral injection compared to that by intravenous injection. Because the half-life of 177Lu is more than six days, a longer accumulation of 177Lu-DTPA-pAuNS in normal organs may possibly endow unexpected side effects [36]. Therefore, intratumoral injection of the nanoparticle-embedded radiopharmaceutical is an interesting approach for HNSCC treatment.
The 5-years survival rate of HNSCC is around 50% after adjuvant chemoradiotherapy [37]. Local invasiveness of HNSCC is associated with EMT and is also a factor that affects the therapeutic efficacy. We have previously shown that intravenous injection of 188Re-liposome radiopharmaceutical could induce let-7i microRNA in orthotopic HNSCC tumors [29]. Furthermore, RNA-seq analysis revealed that a panel of microRNAs with tumor-suppressive and oncogenic characteristics were up-regulated and down-regulated, respectively, in 188Re-liposome treated HNSCC tumors [38]. The expression of EMT molecules was also influenced by 188Re-liposome to account for the potential therapeutic efficacy of this radiopharmaceutical [7]. Current data has shown that the use of intratumoral injection led to significant retention of 177Lu-DTPA-pAuNS in the HNSCC tumor model. However, little is known about the tumor-suppressive mechanisms of 177Lu-DTPA-pAuNS. For precise or personal therapy, it is critical to investigate the therapeutic mechanisms of this novel radiopharmaceutical.
For intravenous injection of 177Lu-DTPA-pAuNS, the radioactivity detected in the SAS xenograft tumor was approximately 1.17 ± 0.13%ID/g and 0.59 ± 0.36%ID/g after 24 h and 48 h, respectively (Figure S1). Most of the radioactivity was detected in the liver and spleen. This result is similar to that observed in our previous study, wherein, we used SKOV-3 xenograft tumors injected with 111In-DTPA-pAuNS intravenously [26]. Regarding the significant anti-tumoral effect of intravenously delivered AuNS-mediated PTT [26], we expected that the tumor-suppressing effect of intratumorally injected AuNS plus laser exposure should be more apparent because of the higher amount of AuNS accumulated in tumor lesions. Unexpectedly, there were no mice with complete tumor regression based on caliper-measured tumor volumes (Figure S2A,B). However, the H&E staining confirmed that the residual masses were nonviable scar tissues rather than live tumor cells (Figure S2C). These results suggest the potential of combining 177Lu-DTPA-pAuNS brachytherapy and PTT against HNSCC.

5. Conclusions

Current data demonstrate the long retention and therapeutic efficacy of the intratumoral injection of 177Lu-DTPA-pAuNS into an orthotopic HNSCC tumor model with little radiation exposure to normal organs. Because AuNS has been applied in PTT for superficial tumor lesions, conjugation of 177Lu with AuNS may provide a novel adjuvant brachytherapy approach for cancer treatment.

Supplementary Materials

The following are available online at https://www.mdpi.com/article/10.3390/pharmaceutics13111903/s1, Table S1: Biodistribution of intravenous injection of 177Lu-DTPA-AuNS in HNSCC orthotopic tumor model; Figure S1: Intravenously injection of 177Lu-DTPA-pAuNS in HNSCC orthotopic tumor model. (A) μSPECT/CT imaging of 177Lu-DTPA-pAuNS. (B) The activity of the tumor area at different time points; Figure S2: Photothermal therapy treatment of pAuNS. (A) Theraml imaging of pAuNS-mediated PTT. (B) Comparison of tumor growth in pAuNS and pAuNS-mediated PTT. (C) H&E staining of HNSCC tumor. The nuclei and the cytoplasm were stained with haematoxylin (blue) and eosin (red).

Author Contributions

Conceptualization, C.-Y.W. and Y.-J.L.; methodology, M.-Y.L. and H.-H.H.; software, H.-H.H.; validation, J.-C.C., C.-L.C. and W.-S.H.; formal analysis, T.-W.C.; investigation, M.-Y.L., H.-H.H. and N.-C.S.; resources, S.-Y.H. and T.-W.C.; data curation, M.-Y.L. and H.-H.H.; writing—original draft preparation, Y.-J.L.; writing—review and editing, C.-Y.W.; visualization, M.-Y.L. and H.-H.H.; supervision, J.-C.C. and S.-Y.H.; project administration, Y.-J.L.; funding acquisition, Y.-J.L. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by an intramural grant of National Yang-Ming University and National Chiao Tung University (109AC-DYC604), and a grant from Ministry of Science and Technology of Taiwan (110-2623-E-010-004-NU and 109-2314-B-010-066).

Institutional Review Board Statement

All the experiment animals were approved by the Institutional Animal Care and Use Committee (IACUC No. 1081009).

Informed Consent Statement

Not applicable.

Data Availability Statement

Data generated or analyzed during the study are available from the corresponding author by request.

Acknowledgments

We thank the support from Cancer Progression Research Center, National Yang Ming Chiao Tung University. We thank the facility supported by the Molecular and Genetic Imaging Core/National Research Program for Genomic Medicine.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Pulte, D.; Brenner, H. Changes in survival in head and neck cancers in the late 20th and early 21st century: A period analysis. Oncologist 2010, 15, 994–1001. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  2. Chang, J.H.; Wu, C.C.; Yuan, K.S.; Wu, A.T.H.; Wu, S.Y. Locoregionally recurrent head and neck squamous cell carcinoma: Incidence, survival, prognostic factors, and treatment outcomes. Oncotarget 2017, 8, 55600–55612. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  3. Garavello, W.; Ciardo, A.; Spreafico, R.; Gaini, R.M. Risk factors for distant metastases in head and neck squamous cell carcinoma. Arch. Otolaryngol. Head Neck Surg. 2006, 132, 762–766. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  4. Yang, W.H.; Lan, H.Y.; Huang, C.H.; Tai, S.K.; Tzeng, C.H.; Kao, S.Y.; Wu, K.J.; Hung, M.C.; Yang, M.H. RAC1 activation mediates Twist1-induced cancer cell migration. Nat. Cell Biol. 2012, 14, 366–374. [Google Scholar] [CrossRef]
  5. Jimenez, L.; Jayakar, S.K.; Ow, T.J.; Segall, J.E. Mechanisms of Invasion in Head and Neck Cancer. Arch. Pathol. Lab. Med. 2015, 139, 1334–1348. [Google Scholar] [CrossRef] [Green Version]
  6. van der Heijden, M.; Essers, P.B.M.; Verhagen, C.V.M.; Willems, S.M.; Sanders, J.; de Roest, R.H.; Vossen, D.M.; Leemans, C.R.; Verheij, M.; Brakenhoff, R.H.; et al. Epithelial-to-mesenchymal transition is a prognostic marker for patient outcome in advanced stage HNSCC patients treated with chemoradiotherapy. Radiother. Oncol. 2020, 147, 186–194. [Google Scholar] [CrossRef]
  7. Chang, C.Y.; Chen, C.C.; Lin, L.T.; Chang, C.H.; Chen, L.C.; Wang, H.E.; Lee, T.W.; Lee, Y.J. PEGylated liposome-encapsulated rhenium-188 radiopharmaceutical inhibits proliferation and epithelial-mesenchymal transition of human head and neck cancer cells in vivo with repeated therapy. Cell Death Discov. 2018, 4, 100. [Google Scholar] [CrossRef] [Green Version]
  8. Ma, Y.; Zhao, G.; Qi, J.; Sun, P.; Liu, C.; Qu, P.; Chan, K.K.L. Neoadjuvant brachytherapy and chemotherapy followed by radical surgery for stage IB2 and IIA cervical cancer: A retrospective comparison with chemoirradiation. Mol. Clin. Oncol. 2018, 8, 617–622. [Google Scholar] [CrossRef]
  9. Sgouros, G.; Bodei, L.; McDevitt, M.R.; Nedrow, J.R. Radiopharmaceutical therapy in cancer: Clinical advances and challenges. Nat. Rev. Drug Discov. 2020, 19, 589–608. [Google Scholar] [CrossRef]
  10. Ritter, M.; Teudt, I.U.; Meyer, J.E.; Schroder, U.; Kovacs, G.; Wollenberg, B. Second-line treatment of recurrent HNSCC: Tumor debulking in combination with high-dose-rate brachytherapy and a simultaneous cetuximab-paclitaxel protocol. Radiat Oncol. 2016, 11, 6. [Google Scholar] [CrossRef] [Green Version]
  11. Bhalavat, R.; Pareek, V.; Chandra, M.; Nellore, L.; George, K.; Borade, D.; Kalariya, K.; Moosa, Z.; Srivastava, A.; Reddy, N.; et al. High-dose-rate interstitial brachytherapy in recurrent head and neck cancer: An effective salvage option. J. Contemp. Brachyther. 2018, 10, 425–430. [Google Scholar] [CrossRef]
  12. Herrero Alvarez, N.; Bauer, D.; Hernandez-Gil, J.; Lewis, J.S. Recent Advances in Radiometals for Combined Imaging and Therapy in Cancer. ChemMedChem 2021, 16, 2909–2941. [Google Scholar] [CrossRef]
  13. Kumar, A.; Ballal, S.; Yadav, M.P.; ArunRaj, S.T.; Haresh, K.P.; Gupta, S.; Damle, N.A.; Garg, A.; Tripathi, M.; Bal, C. 177Lu-/68Ga-PSMA Theranostics in Recurrent Glioblastoma Multiforme: Proof of Concept. Clin. Nucl. Med. 2020, 45, e512–e513. [Google Scholar] [CrossRef]
  14. Das, T.; Banerjee, S. Theranostic Applications of Lutetium-177 in Radionuclide Therapy. Curr. Radiopharm. 2016, 9, 94–101. [Google Scholar] [CrossRef]
  15. Dash, A.; Pillai, M.R.; Knapp, F.F., Jr. Production of (177)Lu for Targeted Radionuclide Therapy: Available Options. Nucl. Med. Mol. Imaging 2015, 49, 85–107. [Google Scholar] [CrossRef] [Green Version]
  16. Muller, C.; van der Meulen, N.P.; Benesova, M.; Schibli, R. Therapeutic Radiometals Beyond (177)Lu and (90)Y: Production and Application of Promising alpha-Particle, beta(-)-Particle, and Auger Electron Emitters. J. Nucl. Med. 2017, 58, 91S–96S. [Google Scholar] [CrossRef] [Green Version]
  17. Khoury, C.G.; Vo-Dinh, T. Gold Nanostars For Surface-Enhanced Raman Scattering: Synthesis, Characterization and Optimization. J. Phys. Chem. C Nanomater. Interfaces 2008, 2008, 18849–18859. [Google Scholar] [CrossRef] [Green Version]
  18. Tian, F.; Conde, J.; Bao, C.; Chen, Y.; Curtin, J.; Cui, D. Gold nanostars for efficient in vitro and in vivo real-time SERS detection and drug delivery via plasmonic-tunable Raman/FTIR imaging. Biomaterials 2016, 106, 87–97. [Google Scholar] [CrossRef] [Green Version]
  19. Chen, H.; Kou, X.; Yang, Z.; Ni, W.; Wang, J. Shape- and size-dependent refractive index sensitivity of gold nanoparticles. Langmuir 2008, 24, 5233–5237. [Google Scholar] [CrossRef]
  20. Hao, F.; Nehl, C.L.; Hafner, J.H.; Nordlander, P. Plasmon resonances of a gold nanostar. Nano Lett. 2007, 7, 729–732. [Google Scholar] [CrossRef]
  21. Mousavi, S.M.; Zarei, M.; Hashemi, S.A.; Ramakrishna, S.; Chiang, W.H.; Lai, C.W.; Gholami, A. Gold nanostars-diagnosis, bioimaging and biomedical applications. Drug Metab. Rev. 2020, 52, 299–318. [Google Scholar] [CrossRef]
  22. Liu, Y.; Yuan, H.; Fales, A.M.; Register, J.K.; Vo-Dinh, T. Multifunctional gold nanostars for molecular imaging and cancer therapy. Front. Chem 2015, 3, 51. [Google Scholar] [CrossRef] [Green Version]
  23. Kim, C.; Song, H.M.; Cai, X.; Yao, J.; Wei, A.; Wang, L.V. In vivo photoacoustic mapping of lymphatic systems with plasmon-resonant nanostars. J. Mater. Chem. 2011, 21, 2841–2844. [Google Scholar] [CrossRef]
  24. Li, C.; Zhang, Y.; Wan, Y.; Wang, J.; Lin, J.; Li, Z.; Huang, P. STING-activating drug delivery systems: Design strategies and biomedical applications. Chin. Chem. Lett. 2021, 32, 1615–1625. [Google Scholar] [CrossRef]
  25. Gherman, A.M.M.; Boca, S.; Vulpoi, A.; Cristea, M.V.; Farcau, C.; Tosa, V. Plasmonic photothermal heating of gold nanostars in a real-size container: Multiscale modelling and experimental study. Nanotechnology 2020, 31, 125701. [Google Scholar] [CrossRef]
  26. Chen, C.C.; Chang, D.Y.; Li, J.J.; Chan, H.W.; Chen, J.T.; Chang, C.H.; Liu, R.S.; Chang, C.A.; Chen, C.L.; Wang, H.E. Investigation of biodistribution and tissue penetration of PEGylated gold nanostars and their application for photothermal cancer treatment in tumor-bearing mice. J. Mater. Chem B 2020, 8, 65–77. [Google Scholar] [CrossRef]
  27. Hernandez-Montoto, A.; Gorbe, M.; Llopis-Lorente, A.; Terres, J.M.; Montes, R.; Cao-Milan, R.; Diaz de Grenu, B.; Alfonso, M.; Orzaez, M.; Marcos, M.D.; et al. A NIR light-triggered drug delivery system using core-shell gold nanostars-mesoporous silica nanoparticles based on multiphoton absorption photo-dissociation of 2-nitrobenzyl PEG. Chem. Commun. 2019, 55, 9039–9042. [Google Scholar] [CrossRef]
  28. Yook, S.; Cai, Z.; Lu, Y.; Winnik, M.A.; Pignol, J.P.; Reilly, R.M. Intratumorally Injected 177Lu-Labeled Gold Nanoparticles: Gold Nanoseed Brachytherapy with Application for Neoadjuvant Treatment of Locally Advanced Breast Cancer. J. Nucl. Med. 2016, 57, 936–942. [Google Scholar] [CrossRef] [Green Version]
  29. Smith, G.L.; Jiang, J.; Buchholz, T.A.; Xu, Y.; Hoffman, K.E.; Giordano, S.H.; Hunt, K.K.; Smith, B.D. Benefit of adjuvant brachytherapy versus external beam radiation for early breast cancer: Impact of patient stratification on breast preservation. Int. J. Radiat. Oncol. Biol. Phys. 2014, 88, 274–284. [Google Scholar] [CrossRef] [Green Version]
  30. Chen, M.; Huang, X.; Lai, J.; Ma, L.; Chen, T. Substituent-regulated highly X-ray sensitive Os(VI) nitrido complex for low-toxicity radiotherapy. Chin. Chem. Lett. 2021, 32, 158–161. [Google Scholar] [CrossRef]
  31. Ma, H.; Wu, Y.; Zhang, W.; Zhang, H.; Miao, Z.; Zhuang, C. Radiosensitization of human pancreatic cancer by piperlongumine analogues. Chin. Chem. Lett. 2021, 32, 1197–1201. [Google Scholar] [CrossRef]
  32. Lee, N.; Hoffman, R.; Phillips, T.L.; Xia, P.; Quivey, J.M.; Weinberg, V.; Hsu, I.C. Managing nasopharyngeal carcinoma with intracavitary brachytherapy: One institution’s 45-year experience. Brachytherapy 2002, 1, 74–82. [Google Scholar] [CrossRef]
  33. Yamazaki, H.; Yoshida, K.; Yoshioka, Y.; Shimizutani, K.; Furukawa, S.; Koizumi, M.; Ogawa, K. High dose rate brachytherapy for oral cancer. J. Radiat Res. 2013, 54, 1–17. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  34. Almeida, J.P.; Chen, A.L.; Foster, A.; Drezek, R. In vivo biodistribution of nanoparticles. Nanomedicine 2011, 6, 815–835. [Google Scholar] [CrossRef]
  35. Long, W.; Wang, J.; Xu, F.; Wu, H.; Mu, X.; Wang, J.; Sun, Y.; Zhang, X.-D. Catalytic PtPd bimetal nanocrystals with high-index facets for radiation injury repair. Chin. Chem. Lett. 2020, 31, 269–274. [Google Scholar] [CrossRef]
  36. Begg, A.C. Predicting recurrence after radiotherapy in head and neck cancer. Semin. Radiat. Oncol. 2012, 22, 108–118. [Google Scholar] [CrossRef]
  37. Lin, L.T.; Chang, C.Y.; Chang, C.H.; Wang, H.E.; Chiou, S.H.; Liu, R.S.; Lee, T.W.; Lee, Y.J. Involvement of let-7 microRNA for the therapeutic effects of Rhenium-188-embedded liposomal nanoparticles on orthotopic human head and neck cancer model. Oncotarget 2016, 7, 65782–65796. [Google Scholar] [CrossRef] [Green Version]
  38. Lin, B.Z.; Wan, S.Y.; Lin, M.Y.; Chang, C.H.; Chen, T.W.; Yang, M.H.; Lee, Y.J. Involvement of Differentially Expressed microRNAs in the PEGylated Liposome Encapsulated (188)Rhenium-Mediated Suppression of Orthotopic Hypopharyngeal Tumor. Molecules 2020, 25, 3609. [Google Scholar] [CrossRef]
Pharmaceutics 13 01903 g001 550
Figure 1. Construction and Radiolabeling of 177Lu labeled PEGylated gold nanostars (177Lu-DTPA-pAuNS). (A) Flow chart of the preparation of 177Lu-DTPA-pAuNS and the application of theranostic strategy. (B,C) RadioTLC analysis shows the labeling efficiency after Lu-177 labeling, EDTA challenge and centrifugation. (D) Transmission electron microscopy (TEM) images of pAuNS and 177Lu-DTPA-pAuNS.
Figure 1. Construction and Radiolabeling of 177Lu labeled PEGylated gold nanostars (177Lu-DTPA-pAuNS). (A) Flow chart of the preparation of 177Lu-DTPA-pAuNS and the application of theranostic strategy. (B,C) RadioTLC analysis shows the labeling efficiency after Lu-177 labeling, EDTA challenge and centrifugation. (D) Transmission electron microscopy (TEM) images of pAuNS and 177Lu-DTPA-pAuNS.
Pharmaceutics 13 01903 g001
Pharmaceutics 13 01903 g002 550
Figure 2. Biodistribution analysis of 177Lu-DTPA (Blue bars) and 177Lu-DTPA-pAuNS (Red bars) after intratumoral injection in orthotopic HNSCC tumor-bearing mice. Radioactivity distribution in each organ is demonstrated by bar chart (n = 4).
Figure 2. Biodistribution analysis of 177Lu-DTPA (Blue bars) and 177Lu-DTPA-pAuNS (Red bars) after intratumoral injection in orthotopic HNSCC tumor-bearing mice. Radioactivity distribution in each organ is demonstrated by bar chart (n = 4).
Pharmaceutics 13 01903 g002
Pharmaceutics 13 01903 g003 550
Figure 3. The evaluation of microSPECT/CT in HNSCC orthotopic tumor after intratumoral injection. (A) microSPECT/CT imaging of 177Lu-DTPA and 177Lu-DTPA-pAuNS accumulations in orthotopic HNSCC tumor-bearing mice. (B) The time activity curve shows the activity of the tumor area circled by the ROI (n = 3). (C,D) The correlation of biodistribution analysis (%ID/g) and semi-quantitative analysis (%ID/cc) in 177Lu-DTPA-pAuNS and 177Lu-DTPA.
Figure 3. The evaluation of microSPECT/CT in HNSCC orthotopic tumor after intratumoral injection. (A) microSPECT/CT imaging of 177Lu-DTPA and 177Lu-DTPA-pAuNS accumulations in orthotopic HNSCC tumor-bearing mice. (B) The time activity curve shows the activity of the tumor area circled by the ROI (n = 3). (C,D) The correlation of biodistribution analysis (%ID/g) and semi-quantitative analysis (%ID/cc) in 177Lu-DTPA-pAuNS and 177Lu-DTPA.
Pharmaceutics 13 01903 g003
Pharmaceutics 13 01903 g004 550
Figure 4. Monitoring the therapeutic efficacy of 177Lu-DTPA-pAuNS administrated in HNSCC tumor-bearing mice. (A) The experimental scheme for 177Lu-DTPA-pAuNS treatment. (B) The bioluminescence imaging of tumor growth responding to 177Lu-DTPA-pAuNS and untreated control. (C) Quantification of the bioluminescence intensity change; *: p < 0.05 (D) The tumor volume of mice in each group. The mice in the control group, 177Lu-DTPA-injected group, and 177Lu-DTPA-pAuNSs-injected group were treated with normal saline, 200 μCi of 177Lu-DTPA and 200 μCi of 177Lu-DTPA-pAuNSs, respectively (n = 5); *: p < 0.05; ns: non-significant.
Figure 4. Monitoring the therapeutic efficacy of 177Lu-DTPA-pAuNS administrated in HNSCC tumor-bearing mice. (A) The experimental scheme for 177Lu-DTPA-pAuNS treatment. (B) The bioluminescence imaging of tumor growth responding to 177Lu-DTPA-pAuNS and untreated control. (C) Quantification of the bioluminescence intensity change; *: p < 0.05 (D) The tumor volume of mice in each group. The mice in the control group, 177Lu-DTPA-injected group, and 177Lu-DTPA-pAuNSs-injected group were treated with normal saline, 200 μCi of 177Lu-DTPA and 200 μCi of 177Lu-DTPA-pAuNSs, respectively (n = 5); *: p < 0.05; ns: non-significant.
Pharmaceutics 13 01903 g004
Pharmaceutics 13 01903 g005 550
Figure 5. (A) The body weight of the mice in each group during the treatment course. The mice in the control group, 177Lu-DTPA-injected group, and 177Lu-DTPA-pAuNSs-injected group were treated with normal saline, 200 μCi of 177Lu-DTPA, and 200 μCi of 177Lu-DTPA-pAuNSs, respectively (n = 5). (B) The percentage of survival for each group at indicated time points.
Figure 5. (A) The body weight of the mice in each group during the treatment course. The mice in the control group, 177Lu-DTPA-injected group, and 177Lu-DTPA-pAuNSs-injected group were treated with normal saline, 200 μCi of 177Lu-DTPA, and 200 μCi of 177Lu-DTPA-pAuNSs, respectively (n = 5). (B) The percentage of survival for each group at indicated time points.
Pharmaceutics 13 01903 g005
Table
Table 1. The biodistribution of 177Lu-DTPA-pAuNS injected intratumorally into tumor-bearing mice a.
Table 1. The biodistribution of 177Lu-DTPA-pAuNS injected intratumorally into tumor-bearing mice a.
Organ b4 h24 h48 h72 h
Blood5.43 ± 3.780.16 ± 0.030.21 ± 0.070.15 ± 0.02
Heart1.14 ± 0.650.27 ± 0.130.23 ± 0.050.17 ± 0.09
Lung2.59 ± 0.950.81 ± 0.440.62 ± 0.330.54 ± 0.27
Liver8.91 ± 4.5017.68 ± 6.4710.43 ± 4.017.85 ± 5.02
Stomach0.59 ± 0.100.36 ± 0.070.39 ± 0.100.31 ± 0.02
Small int.0.81 ± 0.250.61 ± 0.290.74 ± 0.380.24 ± 0.03
Large int.0.51 ± 0.170.20 ± 0.060.25 ± 0.090.15 ± 0.07
Spleen5.99 ± 1.348.49 ± 2.744.85 ± 2.772.53 ± 2.11
Pancreas0.65 ± 0.250.12 ± 0.050.13 ± 0.040.14 ± 0.03
Kidney8.97 ± 1.797.04 ± 2.074.31 ± 0.794.23 ± 1.56
Bone0.65 ± 0.090.88 ± 0.061.74 ± 0.412.20 ± 0.89
Muscle0.28 ± 0.140.07 ± 0.100.10 ± 0.050.04 ± 0.05
Tumor125.09 ± 27.26120.08 ± 51.3235.62 ± 6.8561.44 ± 14.81
BM2.12 ± 1.350.55 ± 1.012.15 ± 0.860.00 ± 0.00
Brain0.16 ± 0.080.02 ± 0.030.02 ± 0.010.03 ± 0.04
Urine183.23 ± 81.0811.41 ± 10.712.04 ± 1.102.49 ± 2.87
T/M377.17 ± 154.531667.36 ± 1827.93354.16 ± 152.191499.10 ± 279.39
T/B23.02 ± 41.25747.62 ± 879.15169.42 ± 71.88416.33 ± 110.57
a Unit: percent of injection dose/gram of organ or tissue (%ID/g); b BM: Bone marrow; T/M: tumor-to-muscle; T/B tumor-to-blood ratio.
Table
Table 2. Radiation dose estimates for intratumoral injection of 177Lu-DTPA-pAuNS in an adult human a.
Table 2. Radiation dose estimates for intratumoral injection of 177Lu-DTPA-pAuNS in an adult human a.
Target Organ bAbsorbed Dose (mSv/MBq)
Adrenals4.92 × 10−3
Brain2.34 × 10−3
Breasts1.50 × 10−3
Gallbladder Wall7.43 × 10−3
LLI Wall5.06 × 10−3
Small Intestine5.62 × 10−3
Stomach Wall7.17 × 10−3
ULI Wall2.52 × 10−3
Heart Wall2.22 × 10−2
Kidneys1.35 × 10−1
Liver3.29 × 10−1
Lungs2.61 × 10−2
Muscle3.53 × 10−3
Ovaries1.48 × 10−3
Pancreas1.18 × 10−2
Red Marrow2.13 × 10−3
Skin1.25 × 10−3
Spleen1.38 × 10−1
Testes9.93 × 10−4
Thymus1.64 × 10−3
Thyroid1.22 × 10−3
Urinary Bladder Wall1.14 × 10−3
Uterus1.38 × 10−3
Tumor (0.5 g) c3.55 × 100
Total Body1.69 × 10−2
Effective Dose2.51 × 10−2
a The radiation dosimetry was converted from the biodistribution of 177Lu-pAuNS in 0.025 kg mice to 73 kg male adults. b LLI: Lower Large Intestine; ULI: Upper Large Intestine. c The tumor absorbed dose was obtained by the sphere model. The unit is mGy/MBq because no organ weighting factor is available for the sphere model.
Table
Table 3. Radiation dose estimates for intravenous injection of 177Lu-DTPA-pAuNS in an adult human a.
Table 3. Radiation dose estimates for intravenous injection of 177Lu-DTPA-pAuNS in an adult human a.
Target Organ bAbsorbed Dose (mSv/MBq)
Adrenals9.06 × 10−2
Brain3.86 × 10−3
Breasts7.09 × 10−2
Gallbladder Wall1.08 × 10−1
LLI Wall7.77 × 10−2
Small Intestine8.76 × 10−2
Stomach Wall8.14 × 10−2
ULI Wall8.02 × 10−2
Heart Wall2.14 × 10−2
Kidneys1.60 × 10−1
Liver1.97 × 100
Lungs6.37 × 10−2
Muscle1.14 × 10−2
Ovaries7.40 × 10−2
Pancreas5.01 × 10−2
Red Marrow5.71 × 10−2
Skin6.83 × 10−2
Spleen1.37 × 100
Testes6.95 × 10−2
Thymus7.19 × 10−2
Thyroid7.03 × 10−2
Urinary Bladder Wall7.23 × 10−2
Uterus7.43 × 10−2
Tumor (0.5 g) c3.82 × 10−2
Total Body1.31 × 10−1
Effective Dose1.71 × 10−1
a The radiation dosimetry was converted from the biodistribution of 177Lu-pAuNS in 0.025 kg mice to 73 kg male adults. b LLI: Lower Large Intestine; ULI: Upper Large Intestine. c The tumor absorbed dose was obtained by the sphere model. The unit is mGy/MBq because no organ weighting factor is available for the sphere model.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Lin, M.-Y.; Hsieh, H.-H.; Chen, J.-C.; Chen, C.-L.; Sheu, N.-C.; Huang, W.-S.; Ho, S.-Y.; Chen, T.-W.; Lee, Y.-J.; Wu, C.-Y. Brachytherapy Approach Using 177Lu Conjugated Gold Nanostars and Evaluation of Biodistribution, Tumor Retention, Dosimetry and Therapeutic Efficacy in Head and Neck Tumor Model. Pharmaceutics 2021, 13, 1903. https://doi.org/10.3390/pharmaceutics13111903

AMA Style

Lin M-Y, Hsieh H-H, Chen J-C, Chen C-L, Sheu N-C, Huang W-S, Ho S-Y, Chen T-W, Lee Y-J, Wu C-Y. Brachytherapy Approach Using 177Lu Conjugated Gold Nanostars and Evaluation of Biodistribution, Tumor Retention, Dosimetry and Therapeutic Efficacy in Head and Neck Tumor Model. Pharmaceutics. 2021; 13(11):1903. https://doi.org/10.3390/pharmaceutics13111903

Chicago/Turabian Style

Lin, Min-Ying, Hsin-Hua Hsieh, Jyh-Cheng Chen, Chuan-Lin Chen, Nin-Chu Sheu, Wen-Sheng Huang, Shinn-Ying Ho, Ting-Wen Chen, Yi-Jang Lee, and Chun-Yi Wu. 2021. "Brachytherapy Approach Using 177Lu Conjugated Gold Nanostars and Evaluation of Biodistribution, Tumor Retention, Dosimetry and Therapeutic Efficacy in Head and Neck Tumor Model" Pharmaceutics 13, no. 11: 1903. https://doi.org/10.3390/pharmaceutics13111903

APA Style

Lin, M. -Y., Hsieh, H. -H., Chen, J. -C., Chen, C. -L., Sheu, N. -C., Huang, W. -S., Ho, S. -Y., Chen, T. -W., Lee, Y. -J., & Wu, C. -Y. (2021). Brachytherapy Approach Using 177Lu Conjugated Gold Nanostars and Evaluation of Biodistribution, Tumor Retention, Dosimetry and Therapeutic Efficacy in Head and Neck Tumor Model. Pharmaceutics, 13(11), 1903. https://doi.org/10.3390/pharmaceutics13111903

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop